Press Releases

09.18.2018

New Sub-group Analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Presented at 2018 HFSA Annual Scientific Meeting

09.17.2018

ATOMWISE ENTERS INTO AN EVALUATION AGREEMENT WITH PFIZER

09.14.2018

Pfizer Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at the 27th European Academy of Dermatology and Venereology (EADV) Congress

09.12.2018

System1 Announces a $25 Million Series A Funding to Advance Integrated Technology Platform for Neurotherapeutics Discovery

09.11.2018

BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients with Advanced Renal Cell Carcinoma in Phase III Study

09.06.2018

CYTOO enters into Research and Option Agreement with Pfizer to develop a target discovery platform for Duchenne Muscular Dystrophy

09.05.2018

4D Molecular Therapeutics Raises $90 Million Series B Financing

09.05.2018

Pfizer Receives Breakthrough Therapy Designation from FDA for PF-06651600, an oral JAK3 Inhibitor, for the Treatment of Patients with Alopecia Areata

09.04.2018

Pfizer Prices $5,000,000,000 Debt Offering

08.30.2018

Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne Muscular Dystrophy

08.22.2018

Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer

08.20.2018

Pfizer Invites Public To View And Listen To Webcast Of August 27 Conference Call With Analysts And Investors To Review Tafamidis Data Presentation At ESC Congress 2018